ProtoKinetix, Inc. has recently amended its filing regarding a private offering, as detailed in a filing submitted to the SEC on November 4, 2026. This event is significant as it indicates the company’s ongoing efforts to secure funding in a competitive industry.

Company Overview

ProtoKinetix, Inc. operates within the pharmaceutical preparations sector, classified under SIC 2834. The company is publicly traded under the ticker PKTX on the OTC exchange. As a smaller reporting company, ProtoKinetix has been working to enhance its financial standing and expand its market presence.

What the Filing Says

The amended filing reveals that ProtoKinetix is conducting a private offering with a total amount of $250,000. According to the filing, “total amount sold” stands at $205,500, leaving a remaining balance of $44,500. The company has opted for a private offering under Rule 506(b), which allows for sales to accredited investors.

Impact

This financial maneuver may affect the company’s ability to fund ongoing projects and research within the pharmaceutical sector. The filing indicates that there are currently six investors involved, all of whom are accredited. As the company works to secure the remaining funds, competitors in the pharmaceutical preparations industry will likely monitor the situation closely.

What's Next

The filing does not say what happens next.